Quest Diagnostics, Secaucus New Jersey; and the Centers for Disease Control and Prevention, Atlanta, Georgia.
Obstet Gynecol. 2022 Jul 1;140(1):99-101. doi: 10.1097/AOG.0000000000004822. Epub 2022 Jun 7.
The study evaluates the effect of the 2020 Centers for Disease Control and Prevention and U.S. Preventive Services Task Force recommendations on hepatitis C virus (HCV) screening among pregnant persons nationally and by health insurance type. The study included 5,048,428 pregnant persons aged 15-44 years with either Medicaid or commercial health insurance who had obstetric panel testing performed by Quest Diagnostics, January 2011-June 2021. Antibody screening for HCV infection increased before and accelerated after the updated recommendations in early 2020. Disparities in HCV testing by health insurance status were substantial over the entire study period. Despite substantial progress in the proportion of pregnant persons screened for HCV infection, current testing rates fall short of universal recommendations.
本研究评估了 2020 年美国疾病控制与预防中心和美国预防服务工作组（U.S. Preventive Services Task Force）关于在全国范围内以及按医疗保险类型对孕妇进行丙型肝炎病毒（HCV）筛查的建议的效果。该研究纳入了 2011 年 1 月至 2021 年 6 月期间接受 Quest Diagnostics 进行的产科检测面板检测的年龄在 15-44 岁、有 Medicaid 或商业健康保险的 5,048,428 名孕妇。在 2020 年初更新建议前后，HCV 感染抗体筛查有所增加且加速。在整个研究期间，HCV 检测的医疗保险状况差异很大。尽管对 HCV 感染孕妇的筛查比例有了很大的提高，但目前的检测率仍未达到普遍建议的水平。
